JP2024507118A5 - - Google Patents
Info
- Publication number
- JP2024507118A5 JP2024507118A5 JP2023547794A JP2023547794A JP2024507118A5 JP 2024507118 A5 JP2024507118 A5 JP 2024507118A5 JP 2023547794 A JP2023547794 A JP 2023547794A JP 2023547794 A JP2023547794 A JP 2023547794A JP 2024507118 A5 JP2024507118 A5 JP 2024507118A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- mol
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148543P | 2021-02-11 | 2021-02-11 | |
| US63/148,543 | 2021-02-11 | ||
| PCT/US2022/016229 WO2022174114A1 (en) | 2021-02-11 | 2022-02-11 | Anti-transferrin receptor fusion proteins and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507118A JP2024507118A (ja) | 2024-02-16 |
| JP2024507118A5 true JP2024507118A5 (cg-RX-API-DMAC7.html) | 2025-02-18 |
Family
ID=82837358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547794A Pending JP2024507118A (ja) | 2021-02-11 | 2022-02-11 | 抗トランスフェリン受容体融合タンパク質及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20240148866A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4291246A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024507118A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116997364A (cg-RX-API-DMAC7.html) |
| MA (1) | MA71665A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022174114A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA71665A (fr) | 2021-02-11 | 2025-05-30 | Denali Therapeutics Inc. | Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation |
| US20260015409A1 (en) * | 2022-09-20 | 2026-01-15 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos |
| TW202432602A (zh) | 2022-12-05 | 2024-08-16 | 法商賽諾菲公司 | 運鐵蛋白受體結合蛋白 |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003032913A2 (en) * | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| JP6280499B2 (ja) * | 2011-07-08 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Fc融合タンパク質の精製方法 |
| JP6616189B2 (ja) * | 2013-12-25 | 2019-12-04 | Jcrファーマ株式会社 | 血液脳関門を通過する新規抗トランスフェリン受容体抗体 |
| CA2990785C (en) * | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| CN109641971B (zh) | 2016-08-25 | 2023-04-04 | Jcr制药股份有限公司 | 抗体融合蛋白的制造方法 |
| TWI833178B (zh) * | 2016-12-26 | 2024-02-21 | 日商Jcr製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| MX2019007824A (es) * | 2016-12-28 | 2019-09-09 | Japan Chem Res | Preparacion liofilizada. |
| BR112020005271A2 (pt) * | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| JP7458404B2 (ja) * | 2018-12-20 | 2024-03-29 | アーマジェン・インコーポレイテッド | イズロン酸-2-スルファターゼ免疫グロブリン融合タンパク質の精製 |
| MA71665A (fr) | 2021-02-11 | 2025-05-30 | Denali Therapeutics Inc. | Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation |
-
2022
- 2022-02-11 MA MA71665A patent/MA71665A/fr unknown
- 2022-02-11 CN CN202280022750.1A patent/CN116997364A/zh active Pending
- 2022-02-11 US US18/276,823 patent/US20240148866A1/en active Pending
- 2022-02-11 JP JP2023547794A patent/JP2024507118A/ja active Pending
- 2022-02-11 EP EP22753465.8A patent/EP4291246A4/en active Pending
- 2022-02-11 WO PCT/US2022/016229 patent/WO2022174114A1/en not_active Ceased
-
2025
- 2025-08-19 US US19/304,134 patent/US20250367284A1/en not_active Abandoned
- 2025-08-19 US US19/304,112 patent/US12636363B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7789871B2 (ja) | グルカゴン様ペプチド1受容体アゴニストおよびそれらの使用 | |
| JP2023517236A5 (cg-RX-API-DMAC7.html) | ||
| KR101949891B1 (ko) | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 | |
| JP6672533B1 (ja) | C5関連疾患の治療または予防用の医薬組成物およびc5関連疾患を治療または予防するための方法 | |
| US20250109191A1 (en) | Methods for altering body composition by administering a gdf8 inhibitor and an activin a inhibitor | |
| EP3337828B1 (en) | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis | |
| EP2994489A2 (en) | Anti-glucagon receptor antibodies and methods of use thereof | |
| US20240092875A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| KR20180084045A (ko) | 비형 간염 표면 항원에 대한 항체 및 그의 용도 | |
| JP2024532426A5 (cg-RX-API-DMAC7.html) | ||
| JP7809067B2 (ja) | 抗セラミド抗体 | |
| TWI808963B (zh) | 使用人類化抗cxcr5抗體治療狼瘡 | |
| CN120693172A (zh) | 用于治疗补体介导的疾病的与因子h融合的抗c5抗体 | |
| US20250134988A1 (en) | Pan-Coronavirus Immunogenic Compositions | |
| CN114127108A (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| US20220332822A1 (en) | Subcutaneous administration of antibodies for the treatment of disease | |
| WO2026072993A1 (en) | Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody | |
| TW202535461A (zh) | 使用抗sirpa抗體治療肝臟疾病或病症 | |
| CN117866092A (zh) | 抗人cd73抗体或其抗原结合片段及其应用 | |
| CN116457370A (zh) | 包含抗原和其醣工程化抗体的免疫组合物 |